CSL Provides Update on its R&D Pipeline

  • Dec 04, 2019 AEDT
  • Team Kalkine

CSL Limited (ASX: CSL) is slowly expanding its Research & Development (R&D) capabilities and pipeline to deliver a highly distinguished product portfolio mix and focusing on a broader range of patients’ unmet needs.

  • The company is building its leadership in plasma therapies by identifying emerging new medicines;
  • To support this approach, CSL has forged targeted innovation partnerships near its R&D locations;
  • CSL also released details on progress for a novel treatment of asthma, which has advanced to Phase 1 trials.

At AEST 01:20PM, the stock was trading at $276.100 per share, down by 0.648% from its previous close.


All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK